HLB, CAR-T 치료제는 LO…리보세라닙과 다른 전략 [현장+]

HLB is diversifying its commercialization strategy by adopting a 'Proof of Concept then License-out' model for its CAR-T pipeline, contrasting with its full-cycle development of Rivoceranib. By targeting the solid tumor market where no FDA-approved CAR-T therapies currently exist, the company is strategically positioning itself for high-value partnerships and a transition into a multi-platform global pharmaceutical entity.